Innovent Biologics’ Tyvyt Secures NMPA Approval for EGFR-Mutated NSCLC Treatment
China-based Innovent Biologics Inc., (HKG: 1801) has announced that the National Medical Products Administration (NMPA)...
Company
Zion Pharma’s ZN-A-1041 Acquired by Roche for Global Development and Commercialization
China-based Zion Pharma Ltd, a biotechnology company specializing in the development of brain-penetrable compounds, has...
Grand Pharmaceutical Group Files NDA for Ophthalmic Analgesic APP13007 with US FDA
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced the filing of a New Drug...
Neuro3 Therapeutics Secures Exclusive License Deal with Lundbeck for KCNQ2 Activator Programs
Neuro3 Therapeutics (Neuro3), a biotechnology company specializing in central nervous system (CNS) diseases with operations...
Organon Reports Q1 2023 Revenue Growth, Highlights Women’s Health and Biosimilars Progress
Organon (NYSE: OGN) has released its financial report for the first quarter of 2023, announcing...
US FDA Nears Regulatory Decision on Junshi Biosciences’ PD-1 Inhibitor Tuoyi
China-based Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) is approaching a significant regulatory milestone...
Acorda Therapeutics Strikes Deal with Hangzhou Chance for Inbrija Distribution in China
US-based Acorda Therapeutics Inc., (Nasdaq: ACOR) has announced a distribution and supply agreement with Hangzhou...
RemeGen Ltd Receives Approval for Phase I Clinical Study of RC198 in Solid Tumors
RemeGen Ltd (HKG: 9995) has announced that it has received approval from the Human Research...
Grand Pharmaceutical Group Completes Enrollment in Phase III Study for Ryaltris Nasal Spray
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced the completion of all subject enrollment...
Alphamab Oncology and CSPC Pharma Get Green Light for KN026 Phase III Study in Breast Cancer
China-based Alphamab Oncology (HKG: 9966) and CSPC Pharmaceutical Group Ltd (HKG: 1093) have announced receiving...
Eyenovia, Inc. Receives FDA Approval for Mydcombi, a First-of-Its-Kind Ophthalmic Spray
US-based Eyenovia, Inc. (NASDAQ: EYEN) has announced obtaining market approval from the US Food and...
Jiangsu Hengrui Pharmaceuticals Advances SHR-1819, SHR-2002, and Adebrelimab into New Clinical Trials
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced receiving clinical trial approvals for its...
Ascletis Pharma Receives Approval for Phase IIa Study of ASC10 for RSV Infection
China-based Ascletis Pharma Inc. (HKG: 1672) has announced receiving the green light to conduct a...
EQRx Inc. Abandons Plans for Low-Cost Drugs, Terminates Development of Three China-Sourced Products
US-based biotech EQRx Inc., (Nasdaq: EQRX) has disclosed in its Q4 2022 financial report a...
Shunxi Holding Group Secures Licensing Deal for Cartherics’ CTH-004 in Greater China
China-based Shunxi Holding Group Co. Ltd has entered into a licensing deal with Australia-based firm...
AstraZeneca’s MEK Inhibitor Koselugo Approved in China for Pediatric NF1-Related PN
UK major AstraZeneca (AZ, NASDAQ: AZN) has announced that its mitogen-activated protein kinase (MEK) inhibitor,...
Shenzhen’s Angio8 Secures Tens of Millions in Series A Financing for Surgical Robot Development
Angio8, a Shenzhen-based developer of vascular interventional surgical robots, has reportedly raised tens of millions...
BeiGene’s Brukinsa Receives NMPA Approval for Expanded Use in Leukemia and Lymphoma
China-based BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has announced that it has received approval...
Shanghai Junshi Biosciences’ Tuoyi Shows Promise in Phase III Study for ES-SCLC
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced encouraging results from the...
Suzhou GenAssist’s GEN6050 Receives US FDA Pre-IND Acceptance for Duchenne Muscular Dystrophy Treatment
China-based Suzhou GenAssist Therapeutic Co., Ltd has announced that the US Food and Drug Administration...